The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced ...
The editor-in-chief of the Journal of the American Heart Association discusses what editors prioritize in research manuscripts, common submission mistakes, and strategies for improving publication ...
Terry Livingston, PharmD, vice president of medical affairs at Octave Bioscience, discussed the evolving role of blood-based biomarkers in multiple sclerosis care. New biomarker data showed smaller ...
A phase 1 clinical trial published in 2026 evaluated BBM-P002, an investigational gene therapy for Parkinson disease. Which ...
Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years ...
One-year data from the phase 3 AQUARELLE study show that divozilimab (Biocad), an anti-CD20 monoclonal antibody, reduced ...
A target trial emulation pooling ACCORD-BP and SPRINT data found calcium channel blocker regimens reduced blood pressure variability without changing cardiovascular outcomes.
The FDA has accepted the resubmitted new drug application (NDA) for troriluzole (Vyglxia; Biohaven) for the treatment of ...
Remibrutinib (Novartis), an oral Bruton tyrosine kinase (BTK) inhibitor, reduced annualized relapse rate (ARR) vs ...
A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral ...
FcRn inhibition targets the persistence of pathogenic IgG rather than its production. The panel explains why this downstream ...
New analyses found differences in functional outcomes over 2 years among patients aged 8 to 12 years treated with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results